Bolivia (Plurinational State of)Tuberculosis profile
Population  2016 11 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.93 (0.67–1.2) 8.6 (6.2–11)
Mortality (HIV+TB only) 0.17 (0.11–0.24) 1.6 (1–2.2)
Incidence  (includes HIV+TB) 12 (8.1–18) 114 (75–162)
Incidence (HIV+TB only) 0.5 (0.32–0.71) 4.6 (2.9–6.6)
Incidence (MDR/RR-TB)** 0.47 (0.23–0.7) 4.3 (2.1–6.5)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.78 (0.48–1.1) 3.8 (2.4–5.3) 4.6 (2.8–6.4)
Males 0.8 (0.5–1.1) 7 (4.3–9.7) 7.8 (4.8–11)
Total 1.6 (0.97–2.2) 11 (6.7–15) 12 (8.1–18)
TB case notifications, 2016  
Total cases notified 7 776
Total new and relapse 7 681
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 77%
          - % pulmonary 79%
          - % bacteriologically confirmed among pulmonary 92%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 62% (44–95)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.09 (0.06–0.14)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 241 4%
          - on antiretroviral therapy 193 80%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  220
(130–310)
Estimated % of TB cases with MDR/RR-TB 2.9% (1.4–4.5) 9.6% (7.2–12)  
% notified tested for rifampicin resistance 10% 85% 1 244
MDR/RR-TB cases tested for resistance to second-line drugs   8
Laboratory-confirmed cases MDR/RR-TB: 70, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 52, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 84% 7 831
Previously treated cases, excluding relapse, registered in 2015 62% 104
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014 75% 55
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (95–100)
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data